Agilent Resolution ctDx FIRST Receives FDA Approval as a Liq

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that the U.S. Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benef...

Related Keywords

United States , American , Alan Sandler , Kenna Anderes , Sam Raha , Dacosta Byfield , Naomi Goumillout , Agilent Technologies Inc , Twitter , Genomics Group , Cancer Center , Drug Administration , Agilent Technologies , Facebook , American Cancer Society , Agilent Resolution , Vice President , Translational Medicine , Chief Medical , Key Statistics , American Cancer , About Lung Cancer Web , Retrospective Analysis , Lung Cancer , Clinicoecon Outcomes , Somatic Mutations , Patient Reported Preferences , Liquid Biopsies , Blood Biomarkers , Comprehensive Cancer , Cancer Manag Res , Prospective Study , Circulating Tumor , Guide Matched Targeted Therapy ,